Are synucleinopathies prion-like disorders?
- PMID: 20846907
- DOI: 10.1016/S1474-4422(10)70213-1
Are synucleinopathies prion-like disorders?
Abstract
A shared neuropathological feature of idiopathic Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy is the development of intracellular aggregates of α-synuclein that gradually engage increasing parts of the nervous system. The pathogenetic mechanisms underlying these neurodegenerative disorders, however, are unknown. Several studies have highlighted similarities between classic prion diseases and these neurological proteinopathies. Specifically, identification of Lewy bodies in fetal mesencephalic neurons transplanted in patients with Parkinson's disease raised the hypothesis that α-synuclein, the main component of Lewy bodies, could be transmitted from the host brain to a graft of healthy neurons. These results and others have led to the hypothesis that a prion-like mechanism might underlie progression of synucleinopathy within the nervous system. We review experimental findings showing that misfolded α-synuclein can transfer between cells and, once transferred into a new cell, can act as a seed that recruits endogenous α-synuclein, leading to formation of larger aggregates. This model suggests that strategies aimed at prevention of cell-to-cell transfer of α-synuclein could retard progression of symptoms in Parkinson's disease and other synucleinopathies.
Copyright © 2010 Elsevier Ltd. All rights reserved.
Similar articles
-
Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?Mov Disord. 2013 Jan;28(1):31-40. doi: 10.1002/mds.25373. Mov Disord. 2013. PMID: 23390095 Review.
-
Neuropathological spectrum of synucleinopathies.Mov Disord. 2003 Sep;18 Suppl 6:S2-12. doi: 10.1002/mds.10557. Mov Disord. 2003. PMID: 14502650 Review.
-
α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.Lancet Neurol. 2011 Mar;10(3):230-40. doi: 10.1016/S1474-4422(11)70014-X. Lancet Neurol. 2011. PMID: 21317042
-
ɑ-Synuclein strains and seeding in Parkinson's disease, incidental Lewy body disease, dementia with Lewy bodies and multiple system atrophy: similarities and differences.Cell Tissue Res. 2018 Jul;373(1):195-212. doi: 10.1007/s00441-018-2839-5. Epub 2018 Apr 27. Cell Tissue Res. 2018. PMID: 29704213 Review.
-
[The role of alpha-synuclein in Parkinson's disease].Neuropsychopharmacol Hung. 2014 Jun;16(2):77-84. Neuropsychopharmacol Hung. 2014. PMID: 24978050 Review. Hungarian.
Cited by
-
Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease.Acta Neuropathol. 2013 Jun;125(6):795-813. doi: 10.1007/s00401-013-1114-9. Epub 2013 Apr 19. Acta Neuropathol. 2013. PMID: 23604588 Free PMC article.
-
Synaptic location is a determinant of the detrimental effects of α-synuclein pathology to glutamatergic transmission in the basolateral amygdala.Elife. 2022 Jul 1;11:e78055. doi: 10.7554/eLife.78055. Elife. 2022. PMID: 35775627 Free PMC article.
-
Adaptation and sensitization to proteotoxic stress.Dose Response. 2013 Aug 5;12(1):24-56. doi: 10.2203/dose-response.13-016.Leak. eCollection 2014 Jan. Dose Response. 2013. PMID: 24659932 Free PMC article.
-
The human olfactory system in two proteinopathies: Alzheimer's and Parkinson's diseases.Transl Neurodegener. 2020 Jun 3;9(1):22. doi: 10.1186/s40035-020-00200-7. Transl Neurodegener. 2020. PMID: 32493457 Free PMC article. Review.
-
Alpha-synuclein and iron: two keys unlocking Parkinson's disease.J Neural Transm (Vienna). 2017 Aug;124(8):973-981. doi: 10.1007/s00702-017-1695-x. Epub 2017 Feb 6. J Neural Transm (Vienna). 2017. PMID: 28168622 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources